Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets
- PMID: 9245845
- PMCID: PMC1717210
- DOI: 10.1136/adc.76.6.495
Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets
Abstract
Aims: Long acting subcutaneous testosterone pellets are of proved efficacy for the treatment of hypogonadal men, but have not been reported as a treatment modality in adolescent boys. Pharmacodynamic studies of subcutaneous testosterone release have shown prolonged normalisation of testosterone levels for at least four months. Administration of a long acting, safe, effective, and convenient form of treatment is desirable when life-long treatment is indicated.
Patients and methods: Eighteen boys (aged 13.9-17.5 years at the start of treatment)-seven with primary hypogonadism, nine with secondary hypogonadism, and two boys being treated with testosterone for tall stature--were given testosterone pellets (8-10 mg/kg) every six months for 18 months. Height, weight, pubertal status, and psychosocial parameters were assessed and follicle stimulating hormone, luteinising hormone, testosterone, prolactin, and lipids were measured at 0, 1, 3, 6, 12, and 18 months. Bone age was measured at 0 and 12 months.
Results: In all boys growth velocity continued appropriately for bone age. Puberty continued to progress in all boys and in two boys the amount of virilisation exceeded that seen with previous treatment with intramuscular testosterone. After testosterone administration, follicle stimulating hormone and luteinising hormone suppressed incompletely in the boys with primary hypogonadism. Serum testosterone ranged from 4.3 to 26.7 nmol/l at three months to less than 10 nmol/l at six months after implantation. Prolactin and lipid levels were normal throughout the study. By report, there was an improvement in mood and emotional wellbeing. No pellet extrusions occurred in a total of 156 pellet insertions.
Conclusions: All boys preferred this mode of testosterone administration to intramuscular injections. Long acting subcutaneous testosterone pellets are safe, efficacious, well tolerated, and convenient, and result in normal physical growth and improved psychological outlook in adolescent hypogonadal boys.
Similar articles
-
Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.Clin Endocrinol (Oxf). 1996 Jul;45(1):61-71. doi: 10.1111/j.1365-2265.1996.tb02061.x. Clin Endocrinol (Oxf). 1996. PMID: 8796140
-
Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.Clin Endocrinol (Oxf). 2003 Jun;58(6):691-5. doi: 10.1046/j.1365-2265.2003.01746.x. Clin Endocrinol (Oxf). 2003. PMID: 12780744
-
Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.J Sex Med. 2014 Jan;11(1):254-61. doi: 10.1111/jsm.12320. Epub 2013 Oct 9. J Sex Med. 2014. PMID: 24119010
-
Disorders of Puberty: An Approach to Diagnosis and Management.Am Fam Physician. 2017 Nov 1;96(9):590-599. Am Fam Physician. 2017. PMID: 29094880 Review.
-
Hypogonadism in Male Infants and Adolescents: New Androgen Formulations.Horm Res Paediatr. 2023;96(6):581-589. doi: 10.1159/000521455. Epub 2021 Dec 16. Horm Res Paediatr. 2023. PMID: 34915486 Review.
Cited by
-
Androgen replacement therapy: present and future.Drugs. 2004;64(17):1861-91. doi: 10.2165/00003495-200464170-00002. Drugs. 2004. PMID: 15329035 Review.
-
Androgen Treatment in Adolescent Males With Hypogonadism.Am J Mens Health. 2020 May-Jun;14(3):1557988320922443. doi: 10.1177/1557988320922443. Am J Mens Health. 2020. PMID: 32448030 Free PMC article. Review.
-
Obesity and Hypogonadism-A Narrative Review Highlighting the Need for High-Quality Data in Adolescents.Children (Basel). 2019 May 1;6(5):63. doi: 10.3390/children6050063. Children (Basel). 2019. PMID: 31052376 Free PMC article. Review.
-
New long-acting androgens.World J Urol. 2003 Nov;21(5):306-10. doi: 10.1007/s00345-003-0364-x. Epub 2003 Oct 9. World J Urol. 2003. PMID: 14551719 Review.
-
The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy.Neuromuscul Disord. 2021 Dec;31(12):1259-1265. doi: 10.1016/j.nmd.2021.09.007. Epub 2021 Sep 25. Neuromuscul Disord. 2021. PMID: 34702655 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources